Comparison
Citicoline vs Methylene Blue
Side-by-side of Citicoline and Methylene Blue. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Citicoline
Citicoline supplement profile: CDP-choline as a phosphatidylcholine precursor, Cognizin dosing 250-2000 mg, cognition trials, stroke recovery evidence.
Methylene Blue
Methylene blue as a nootropic: low-dose cognitive enhancement, mitochondrial electron cycling, brain oxygen uptake, SSRI interaction risk, typical 0.5 to 4 mg.
Effects at a glance
Citicoline
- •Choline donor and phosphatidylcholine precursor; oral bioavailability roughly 99%
- •Standard prescription medication for stroke recovery and vascular cognitive impairment in much of the world
- •Healthy-adult cognitive trials (Cognizin) report small gains in attention and working memory at 250 to 500 mg/day
- •ICTUS trial (n=2,298) was negative on stroke recovery in the modern thrombolysis era
- •Lower per-gram choline content than alpha-GPC (~18% vs ~40%), meaning smaller TMAO load at equivalent dose
- •Long uridine half-life (~56 hours) supports once or twice daily dosing
Methylene Blue
- •FDA approved for methemoglobinemia and ifosfamide-induced encephalopathy
- •Mitochondrial electron-transport support at low doses (0.5 to 4 mg/kg) via cytochrome c shuttle
- •Potent MAO-A inhibitor; serotonin syndrome risk with SSRIs, SNRIs, MAOIs, fentanyl, tramadol, St John's wort
- •Causes harmless blue-green urine and sweat coloration; useful adherence marker
- •G6PD deficiency is an absolute contraindication; can trigger massive hemolysis
- •Cognitive-enhancement evidence is preliminary, mostly preclinical and small fMRI trials
Side-by-side
| Attribute | Citicoline | Methylene Blue |
|---|---|---|
| Category | supplement | pharmaceutical |
| Also known as | CDP-choline, cytidine 5'-diphosphocholine, Cognizin | Methylthioninium chloride, Provayblue, tetramethylthionine chloride |
| Half-life (hr) ↗ | 56 | 5.5 |
| Typical dose (mg) ↗ | 500 | 70 |
| Dosing frequency | 1 to 2 times daily | 1 to 3 times daily for cognitive use; single IV dose for methemoglobinemia |
| Routes | oral, intravenous | oral, intravenous |
| Onset (hr) | 1 | 1 |
| Peak (hr) | 2 | 1.5 |
| Molecular weight | 488.32 | 319.85 |
| Molecular formula | C14H26N4O11P2 | C16H18ClN3S |
| Mechanism | Hydrolyzed to cytidine and choline after absorption; both cross the blood-brain barrier and are recombined intracellularly to reform CDP-choline, supporting phosphatidylcholine synthesis and acetylcholine production. | Mitochondrial electron carrier at low doses (cytochrome c shuttle to complex IV) and methemoglobin reductase substrate at higher doses; potent MAO-A inhibitor across the dose range. |
| Legal status | Dietary supplement (US, Cognizin GRAS); prescription medication in most of the world | Prescription (injectable, FDA approved); supplement form (oral) widely available; not scheduled |
| WADA status | allowed | allowed |
| DEA / Rx | OTC supplement (US); Rx in most of the world | Not scheduled in the US |
| Pregnancy | Insufficient data for routine use | Contraindicated |
| CAS | 987-78-0 | 61-73-4 |
| PubChem CID | 13804 | 6099 |
| Wikidata | Q411470 | Q409021 |
Safety profile
Citicoline
Common side effects
- mild GI upset
- headache
- restlessness
- occasional insomnia with evening dosing
Contraindications
- concurrent strong anticholinergic therapy
- established cardiovascular disease (TMAO concern, smaller than alpha-GPC)
Interactions
- anticholinergic medications: partial mutual antagonism(minor)
- cholinesterase inhibitors: additive cholinergic effect(minor)
- antimetabolite chemotherapy (5-FU): theoretical cytidine pathway interaction(minor)
Methylene Blue
Common side effects
- blue-green urine and sweat
- skin and oral mucosa staining
- GI upset
- headache
- dizziness
Contraindications
- G6PD deficiency
- pregnancy
- concurrent serotonergic medication
- severe renal impairment
- infants under 6 months
Interactions
- SSRIs and SNRIs: serotonin syndrome, potentially fatal(major)
- MAOIs: additive MAO inhibition, serotonin syndrome risk(major)
- fentanyl, tramadol, meperidine: serotonin syndrome risk(major)
- dextromethorphan: serotonin syndrome risk(major)
- St John's wort: serotonin syndrome risk(major)
- lithium: additive serotonergic risk(major)
Which Should You Take?
Citicoline comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-B outcome catalogued. Methylene Blue is the right call when one of the conditionals below applies.
- → If your priority is stroke recovery, pick Citicoline.
- → If your priority is choline supply, pick Citicoline.
- → If your priority is mitochondrial function, pick Methylene Blue.
- → If your priority is antimicrobial action, pick Methylene Blue.
Edge case: If you want to avoid controlled substance, Citicoline is the more accessible choice.
Default choice: Citicoline. Lower friction to source, and broader goal coverage. Reach for Methylene Blue only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Citicoline and Methylene Blue?
Citicoline and Methylene Blue differ in category (supplement vs pharmaceutical), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Citicoline or Methylene Blue?
Citicoline half-life is 56 hours; Methylene Blue half-life is 5.5 hours.
Can you stack Citicoline with Methylene Blue?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper